Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LPD004
MIFTS: 46

Lipoid Nephrosis

Categories: Rare diseases, Nephrological diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lipoid Nephrosis

About this section

MalaCards integrated aliases for Lipoid Nephrosis:

Name: Lipoid Nephrosis 12 15 73
Minimal Change Disease 12 53
Nephrotic Syndrome with Lesion of Minimal Change Glomerulonephritis 12
Nephrotic Syndrome with Lesion of Minimal Change Nephrotic Syndrome 12
Idiopathic Minimal Change Nephrotic Syndrome 53
Glomerulonephritis, Minimal Change 73
Nephrotic Syndrome, Minimal Change 73
Minimal Change Glomerulonephritis 12
Minimal Change Nephrotic Syndrome 53
Nephrotic Syndrome Minimal Change 55
Minimal Change Glomerulopathy 53
Nephrosis, Lipoid 44
Mcns 53

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:10966
ICD10 33 N04
MeSH 44 D009402
NCIt 50 C34844
SNOMED-CT 68 197592009 44785005
Sources

Summaries for Lipoid Nephrosis

About this section
NIH Rare Diseases : 53 Minimal change disease is a kidney disease in which there is damage to the filtering units of the kidney (glomeruli). It is the most common cause of nephrotic syndrome in children. Nephrotic syndrome is comprised of a group of symptoms including protein in the urine (proteinuria), low protein levels in the blood, high cholesterol and triglycerides, an increased risk for blood clots, and swelling. Other features of this disease include weight gain and a foamy appearance of the urine. The cause of minimal change disease is unknown, but it may occur following an allergic reaction or infection. Treatment may involve the use of steroids.

MalaCards based summary : Lipoid Nephrosis, also known as minimal change disease, is related to mesangial proliferative glomerulonephritis and focal segmental glomerulosclerosis 1. An important gene associated with Lipoid Nephrosis is NPHS1 (NPHS1, Nephrin), and among its related pathways/superpathways are NF-kappaB Signaling and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Methylprednisolone and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and t cells, and related phenotype is renal/urinary system.

Wikipedia : 76 Minimal change disease (also known as MCD and nil disease, among others) is a disease affecting the... more...

Sources

Related Diseases for Lipoid Nephrosis

About this section

Diseases related to Lipoid Nephrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 137)
# Related Disease Score Top Affiliating Genes
1 mesangial proliferative glomerulonephritis 32.4 CCL2 CD79A
2 focal segmental glomerulosclerosis 1 30.8 CD2AP NPHS1 NPHS2
3 diffuse glomerulonephritis 30.7 ALB CD79A
4 focal segmental glomerulosclerosis 30.7 ALB CD2AP NPHS1 NPHS2 SYNPO
5 glomerulonephritis 29.6 ALB CCL2 CD79A NPHS1 NPHS2
6 nephrotic syndrome 29.2 ALB CD2AP NPHS1 NPHS2 SYNPO
7 membranous nephropathy 28.5 ALB CD2AP CD79A NPHS1 NPHS2 SERPINB7
8 iga glomerulonephritis 26.3 ALB CCL2 CD2AP CD79A NAGLU NPHS1
9 idiopathic steroid-sensitive nephrotic syndrome with minimal change 10.9
10 ascaridiasis 10.8 IL10 IL13
11 c1q nephropathy 10.8
12 trichuriasis 10.8 IL10 IL13
13 apple allergy 10.8 IL10 IL13
14 beta-lactam allergy 10.8 IL10 IL13
15 familial idiopathic steroid-resistant nephrotic syndrome with minimal changes 10.8 NPHS1 NPHS2
16 immunoglobulin a deficiency 1 10.8 CD79A IL10
17 sporotrichosis 10.8 CD79A IL10
18 cow milk allergy 10.7 CD79A IL10
19 hypoparathyroidism, sensorineural deafness, and renal disease 10.7 NPHS1 NPHS2
20 peanut allergy 10.7 IL10 IL13
21 strongyloidiasis 10.7 CD79A IL13
22 clonorchiasis 10.7 CD79A IL10
23 sporadic idiopathic steroid-resistant nephrotic syndrome with focal segmental hyalinosis 10.7 CD2AP NPHS2
24 cork-handlers' disease 10.7 ALB CD79A
25 ostertagiasis 10.7 ALB CD79A
26 dermatitis, atopic, 3 10.6 ALB CD79A
27 orofacial granulomatosis 10.6 CD79A IL10
28 fascioliasis 10.6 ALB IL10
29 coccidiosis 10.6 CD79A IL10
30 root caries 10.6 ALB CD79A
31 parotitis 10.6 ALB CD79A
32 orthostatic proteinuria 10.6 ALB CD79A
33 focal dermal hypoplasia 10.6 ALB CD79A
34 hemorrhagic fever 10.6 ALB IL10
35 pollen allergy 10.6 CD79A IL13
36 non-secretory myeloma 10.6 ALB CD79A
37 hypersensitivity reaction type iii disease 10.6 ALB CD79A
38 protein-losing enteropathy 10.5 ALB CD79A
39 ulcerative stomatitis 10.5 ALB CD79A
40 conjunctival disease 10.5 CD79A IL13
41 paranasal sinus disease 10.5 CD79A IL10 IL13
42 nonspecific interstitial pneumonia 10.5 CCL2 IL13
43 nose disease 10.5 CD79A IL10 IL13
44 acute proliferative glomerulonephritis 10.5 CCL2 CD79A
45 parasitic helminthiasis infectious disease 10.5 CD79A IL10 IL13
46 upper respiratory tract disease 10.5 CD79A IL10 IL13
47 tick-borne encephalitis 10.5 ALB IL10
48 pneumocystosis 10.5 ALB CD79A
49 allergic hypersensitivity disease 10.4 CD79A IL10 IL13
50 tetanus 10.4 CD79A IL10 IL13

Graphical network of the top 20 diseases related to Lipoid Nephrosis:



Diseases related to Lipoid Nephrosis
Sources

Symptoms & Phenotypes for Lipoid Nephrosis

About this section

MGI Mouse Phenotypes related to Lipoid Nephrosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.17 ALB CD2AP CD79A NAGLU NPHS1 NPHS2
Sources

Drugs & Therapeutics for Lipoid Nephrosis

About this section

Drugs for Lipoid Nephrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 69)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 83-43-2 6741
2
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-24-8 5755
3
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3 104987-11-3 445643 439492
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 53-03-2 5865
5
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
6
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 1406-16-2
7 Adrenocorticotropic Hormone Phase 4
8 beta-endorphin Phase 4
9 Hormone Antagonists Phase 4,Phase 3,Not Applicable
10 Hormones Phase 4,Phase 3,Not Applicable
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Not Applicable
12 Immunoglobulin A Phase 4,Not Applicable
13 Melanocyte-Stimulating Hormones Phase 4
14 Antiemetics Phase 4,Phase 3,Not Applicable
15 Anti-Inflammatory Agents Phase 4,Phase 3,Not Applicable
16 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Not Applicable
17 Autonomic Agents Phase 4,Phase 3,Not Applicable
18 Calcineurin Inhibitors Phase 4,Phase 2,Phase 3
19 Gastrointestinal Agents Phase 4,Phase 3,Not Applicable
20 glucocorticoids Phase 4,Phase 3,Not Applicable
21 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
22 Methylprednisolone acetate Phase 4,Phase 3,Not Applicable
23 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Not Applicable
24 Neuroprotective Agents Phase 4,Not Applicable
25 Peripheral Nervous System Agents Phase 4,Phase 3,Not Applicable
26 Prednisolone acetate Phase 4,Phase 3,Not Applicable
27 Prednisolone hemisuccinate Phase 4,Phase 3,Not Applicable
28 Prednisolone phosphate Phase 4,Phase 3,Not Applicable
29 Protective Agents Phase 4,Not Applicable
30 Bone Density Conservation Agents Phase 4,Not Applicable
31 Hydroxycholecalciferols Phase 4
32 Micronutrients Phase 4,Not Applicable
33 Trace Elements Phase 4,Not Applicable
34 Vitamins Phase 4,Not Applicable
35
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
36
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
37
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
38
Mycophenolic acid Approved Phase 3 24280-93-1 446541
39
Valproic Acid Approved, Investigational Phase 2, Phase 3 99-66-1 3121
40 Antirheumatic Agents Phase 3,Phase 2
41 BB 1101 Phase 3
42 Dexamethasone acetate Phase 3 1177-87-3
43 HIV Protease Inhibitors Phase 3
44
protease inhibitors Phase 3
45 Antibodies Phase 3,Not Applicable
46 Antibodies, Monoclonal Phase 3
47 Immunoglobulins Phase 3,Not Applicable
48 Anti-Bacterial Agents Phase 3
49 Antibiotics, Antitubercular Phase 3
50 Anti-Infective Agents Phase 3

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) Completed NCT01129284 Phase 4 ACTHAR gel
2 Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease Recruiting NCT00982072 Phase 4 tacrolimus;prednisolone
3 Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy Recruiting NCT03210688 Phase 4 Prednisolone;Alfacalcidol
4 Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS) Completed NCT00981838 Phase 3 Rituximab
5 Therapeutic Effect of Tacrolimus in Combination With Low Dose Corticosteroid in Adult Patient With Minimal Change Nephritic Syndrome Completed NCT01084980 Phase 2, Phase 3 Tacrolimus
6 Steroid Treatment for Kidney Disease Completed NCT00065611 Phase 3 Oral dexamethasone
7 Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome Completed NCT02438982 Phase 3 Tacrolimus;Rituximab
8 Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood Completed NCT01268033 Phase 2, Phase 3 Rituximab;Placebo
9 Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome Completed NCT01197040 Phase 3 Prednisone;acid mycophenolic (Myfortic)
10 Valproic Acid for Idiopathic Nephrotic Syndrome Recruiting NCT02896270 Phase 2, Phase 3 Valproic Acid
11 Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome Not yet recruiting NCT03298698 Phase 3 Rituximab;Prednisone
12 Podocyte Retinoids Completed NCT00098020 Phase 2 Isotretinoin
13 Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) Recruiting NCT02592798 Phase 2 Abatacept
14 A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases Completed NCT02639260 Phase 1 N-acetyl-mannosamine (ManNAc)
15 The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy Completed NCT01451710 Not Applicable Prednisone or Prednisolone
16 MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics Completed NCT02869893 Not Applicable Secretin
17 Kidney Disease Biomarkers Completed NCT00255398
18 Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients Completed NCT01470183
19 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study Completed NCT01663129
20 Nephrotic Syndrome Study Network Recruiting NCT01209000
21 Diagnostic Value of Linked Color Imaging for Minimal Change Esophagitis in Nonerosive Reflux Esophagitis and GERD Recruiting NCT03068572
22 Study of The Association of Mutations in The NPHS2 Gene and Nephrotic Syndrome in Children and Adults in Middle East Recruiting NCT03326037
23 INSIGHT (Insight Into Nephrotic Syndrome) Recruiting NCT01605266
24 The Canadian Glomerulonephritis Registry and Translational Research Initiative Recruiting NCT03460054
25 Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure Recruiting NCT02194582
26 Vitamin D Supplementation in Glomerular Disease Suspended NCT01835639 Not Applicable

Search NIH Clinical Center for Lipoid Nephrosis

Cochrane evidence based reviews: nephrosis, lipoid

Sources

Genetic Tests for Lipoid Nephrosis

About this section
Sources

Anatomical Context for Lipoid Nephrosis

About this section

MalaCards organs/tissues related to Lipoid Nephrosis:

41
Kidney, Bone, T Cells, Monocytes
Sources

Publications for Lipoid Nephrosis

About this section

Articles related to Lipoid Nephrosis:

(show top 50) (show all 115)
# Title Authors Year
1
50 Years Ago in TheJournal ofPediatrics: Effect of Cyclophosphamide on Lipoid Nephrosis in the Human and on Aminonucleoside Nephrosis in the Rat. ( 27017462 )
2016
2
Cytokine mRNA profile in lipoid nephrosis: evidence for increased IL-8 mRNA stability. ( 12138264 )
2002
3
T-cell lineage acute lymphoblastic leukemia with chromosome 5 abnormality in a patient with Crohn's disease and lipoid nephrosis. ( 10834511 )
2000
4
Changing perspective of lipoid nephrosis in Iranian children. ( 9874333 )
1998
5
Interleukin 12 upregulates the release of vascular permeability factor by peripheral blood mononuclear cells from patients with lipoid nephrosis. ( 9578066 )
1998
6
Anti-interleukin 8 antibody abolishes effects of lipoid nephrosis cytokine. ( 9686956 )
1998
7
Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis. ( 9346389 )
1997
8
Interleukin 10 inhibits vascular permeability factor release by peripheral blood mononuclear cells in patients with lipoid nephrosis. ( 9041534 )
1997
9
Decreased release of IL-10 by monocytes from patients with lipoid nephrosis. ( 8536379 )
1995
10
Effect of lipoid nephrosis cytokine on glomerular sulfated compounds and albuminuria. ( 8580016 )
1995
11
Recombinant granulocyte-macrophage colony-stimulating factor modulates in vitro function of the peripheral blood mononuclear cells in lipoid nephrosis. ( 8342574 )
1993
12
Proteinuria selectivity index--prognostic value in lipoid nephrosis and related diseases. ( 8247178 )
1993
13
Inner ear damage due to lipoid nephrosis. ( 8357609 )
1993
14
Acquired factor VIII autoantibody (AAb) in the course of lipoid nephrosis. ( 8302482 )
1993
15
Effect of methylprednisolone pulse therapy on cellular immunity abnormalities in a patient with lipoid nephrosis. ( 2077423 )
1990
16
[Renin activity and aldosterone level in the plasma of children with lipoid nephrosis]. ( 2251209 )
1990
17
Decreased production of interleukin-1 by monocytes from patients with lipoid nephrosis. ( 2787718 )
1989
18
Ibuprofen-associated lipoid nephrosis without interstitial nephritis. ( 2741936 )
1989
19
Interferon and lipoid nephrosis. ( 2458041 )
1988
20
A transient monocyte defective function in idiopathic nephrotic syndrome (lipoid nephrosis). ( 3170113 )
1988
21
An overlapping syndrome of IgA nephropathy and lipoid nephrosis. ( 3538845 )
1986
22
Evaluation of T colony-stimulating factor in patients with lipoid nephrosis. ( 3484545 )
1986
23
Impaired T-lymphocyte colony formation in lipoid nephrosis. ( 3878248 )
1985
24
Impaired cellular immune responses in adult lipoid nephrosis patients. ( 4017301 )
1985
25
Depression of local graft-versus-host reaction in patients with lipoid nephrosis. ( 3876448 )
1985
26
Defective cell-mediated immunity in lipoid nephrosis. ( 6230321 )
1984
27
Impaired delayed hypersensitivity in lipoid nephrosis. ( 6462316 )
1984
28
Is house dust allergen a possible causal factor for relapses in lipoid nephrosis? ( 6711772 )
1984
29
Alterations of T cell subpopulations in childhood lipoid nephrosis and its relation to immunosuppressive treatment. ( 6335580 )
1984
30
Allergy and lipoid nephrosis. ( 6404133 )
1983
31
Adult onset lipoid nephrosis is not DR7 associated. ( 6415866 )
1983
32
HLA-DR 7 in adult lipoid nephrosis patients. Significant difference according to the age of onset. ( 6603586 )
1983
33
Effect of thymic humoral factor on a local graft-versus-host reaction of lymphocytes in patients with lipoid nephrosis. ( 6984140 )
1982
34
Is lipoid nephrosis an "allergic" disease? ( 6217600 )
1982
35
Renal vein thrombosis complicating lipoid nephrosis. ( 7113197 )
1982
36
Deacetyl-thymosin alpha 1: synthesis and immunological effect on lipoid nephrosis lymphocytes. ( 7116512 )
1982
37
Impaired local graft-versus-host reaction in lipoid nephrosis. ( 6981777 )
1982
38
The treatment of minimal change nephrotic syndrome (lipoid nephrosis): cooperative studies of the Arbeitsgemeinschaft fA1r PAodiatrische Nephrologie (APN). ( 6752557 )
1982
39
Fenoprofen nephropathy: lipoid nephrosis and interstitial nephritis. A possible T-lymphocyte disorder. ( 6977270 )
1982
40
In vitro lymphocyte dysfunction in lipoid nephrosis mediated by suppressor cells. ( 6218418 )
1982
41
Concanavalin A-induced suppressor cell activity in lipoid nephrosis. ( 6458879 )
1981
42
Impaired cell-mediated immunity in lipoid nephrosis. ( 6977099 )
1981
43
Lipoid nephrosis appearing as acute oliguric renal failure. ( 7362359 )
1980
44
Lipoid nephrosis in the elderly. ( 7394611 )
1980
45
Congenital lipoid nephrosis with left renal vein thrombosis and Chiari's syndrome. ( 468879 )
1979
46
Significance of complement (C3) in lipoid nephrosis and glomerulonephritis. ( 730303 )
1978
47
Lipoid nephrosis and focal glomerulosclerosis. ( 355987 )
1978
48
Hodgkin's disease and lipoid nephrosis. ( 67327 )
1977
49
Nephrotic syndrome with minimal glomerular lesions (lipoid nephrosis) in an adult diabetic patient. ( 576799 )
1977
50
A study of the renal handling of water in lipoid nephrosis. ( 1250649 )
1976
Sources

Variations for Lipoid Nephrosis

About this section
Sources

Expression for Lipoid Nephrosis

About this section
Search GEO for disease gene expression data for Lipoid Nephrosis.
Sources

Pathways for Lipoid Nephrosis

About this section

Pathways related to Lipoid Nephrosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
NF-kappaB Signaling 4
12.07 CCL2 CD2AP CD79A IL10
2
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.79 IL10 IL13 TF
3
Interleukin-4 and 13 signaling 66
11.55 CCL2 IL10 IL13
4
Interleukin-10 signaling 66
11.02 CCL2 IL10 IL13
5
Cytokines and Inflammatory Response 1
10.93 IL10 IL13
6
OX40 Pathway 64
10.85 IL10 IL13
7
Primary Focal Segmental Glomerulosclerosis FSGS 1
10.79 CD2AP NPHS1 NPHS2 SYNPO
8
Nephrin interactions 66
10.71 CD2AP NPHS1
9
Nephrin/Neph1 signaling in the kidney podocyte 1
10.55 CD2AP NPHS1 NPHS2
Sources

GO Terms for Lipoid Nephrosis

About this section

Cellular components related to Lipoid Nephrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 ALB CCL2 IL10 IL13 SERPINB7 TF
2 slit diaphragm GO:0036057 8.62 NPHS1 NPHS2

Biological processes related to Lipoid Nephrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 excretion GO:0007588 9.26 NPHS1 NPHS2
2 negative regulation of endothelial cell apoptotic process GO:2000352 9.16 IL10 IL13
3 B cell proliferation GO:0042100 8.96 CD79A IL10
4 positive regulation of macrophage activation GO:0043032 8.62 IL10 IL13

Molecular functions related to Lipoid Nephrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.8 CCL2 IL10 IL13
Sources

Sources for Lipoid Nephrosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....